Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E
Published in Osteoporosis International
Methodology
Three-year randomised, double-blind, placebo-controlled trial of menaquinone-7 180 mcg/day in 244 healthy postmenopausal women.
Key Findings
MK-7 improved vitamin K status, decreased age-related decline in lumbar spine and femoral neck bone mineral density and reduced vertebral height loss.
Conclusions
Low-dose MK-7 slows postmenopausal bone loss over three years.
Limitations
Single centre, healthy volunteers, no fracture endpoints, industry-supplied supplement.
Supplements Studied
MK-7 180 mcg/day decreased the age-related decline in lumbar spine and femoral neck bone mineral density.
MK-7 improved vitamin K status, decreased age-related decline in lumbar spine and femoral neck bone mineral density and reduced vertebral height loss.
Outcomes Measured
MK-7 decreased the age-related decline in lumbar spine and femoral neck bone mineral density.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.